{
    "nct_id": "NCT06095505",
    "official_title": "A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Aged â‰¥18 years at signing of informed consent\n* Pathologically confirmed SCLC\n* Prior treatment with one platinum-based chemotherapy and an anti-PD-L1 immunotherapy. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting\n\nNote: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.",
    "miscellaneous_criteria": ""
}